





# PIPELINE

## Candidate: Lasofoxifene – Oral SERM

Monotherapy ●  
 Combination Therapy ●●

### ► Breast Cancer

	Preclinical	Phase 1	Phase 2	Phase 3/4
●	ELAINE 1: Lasofoxifene vs. Fulvestrant 			
●●	ELAINE 2: Laso + Abemaciclib 			
●	ELAINE 3: Lasofoxifene vs. Fulvestrant 			
●●	ELAINE 4: Laso + CDK 4/6 Inhibitor 			
●●	Laso + mTOR Inhibitor			
●●	Laso + AKT Inhibitor			

In Planning  
 Enrollment Complete  
 Potentially Registrational

*Lilly*

**tbcrc**

## ▶ Treatment Resistant Tumors (non-ESR1<sup>mut</sup>) and ESR1<sup>mut</sup>

- 
- 

Laso vs. Fulv

Laso + Palbo  
vs. Fulv + Palbo

## ▶ Gynecological Cancer

- /••

Lasofloxifene –  
Endometrial  
Cancer

## ▶ ESR1 Assay

Research Assay

Clinical Trial  
Assay (CTA)

CTA/CDx

THE UNIVERSITY OF  
CHICAGO

UNIVERSITY OF UTAH  
HUNTSMAN  
CANCER INSTITUTE